Matthew J. Frigault, M.d.

This early study tested the safety of a treatment called tisagenlecleucel in 13 people with primary central nervous system lymphoma, a rare type of brain cancer. The treatment uses specially engineered immune cells (CAR T cells) to target and attack cancer cells. The main goal wa…